1000 Miglia 2025, Official List of Accepted Cars
BRESCIA, Italy, April 04, 2025 (GLOBE NEWSWIRE) — The wait is over: the list of cars that will participate in the 1000 Miglia 2025 has been drawn up by the Selection Committee that, year after year, has the... More >>
IdentiFlight and Roc Conservation Tech Partner to Advance AI-Powered Bird Conservation for South African Wind Farms
LOUISVILLE, Colo., April 04, 2025 (GLOBE NEWSWIRE) — Boulder Imaging has announced a partnership with Roc Conservation Tech to expand IdentiFlight's global reach and enhance wildlife conservation within the wind energy sector. With a shared... More >>
‘Energy Transfer’s Lawsuit Against Greenpeace Is an Attempt to Drain Our Resources and Silence Dissent’
By CIVICUS
Apr 4 2025 -
CIVICUS speaks with Daniel Simons, Senior Legal Counsel Strategic Defence for Greenpeace International, about the lawsuit brought by an oil and gas company against Greenpeace and its broader implications for civil society.... More >>
Putting People First: Why SRHR Must Be Central to Health and Development Agendas
Credit: World Health Organization... More >> 
NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) —
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or... More >>
TMDX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 15 Deadline in Securities Class Action Commenced by the Firm – TMDX
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) —
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28,... More >>
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MNV–201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Rare... More >>
More >> Cidades globais livres (Free Global Cities): uma nova visão para transformar a crise migratória em uma oportunidade
ZURIQUE, April 03, 2025 (GLOBE NEWSWIRE) — À medida que as abordagens convencionais falham, Free Global Cities: The Future Leaders in Migration and Public Governance propõe uma alternativa ousada — cidades... More >>
Saudi Riyal Exchange Rate